Loading clinical trials...

Near-infrared Light Therapy Device for Mild-Moderate Alzheimer's Disease (NirsCure-03A) | Clinical Trials | Clareo Health

RECRUITINGPHASE3

Near-infrared Light Therapy Device for Mild-Moderate Alzheimer's Disease (NirsCure-03A)

A Multicenter, Randomized, Double-Blind, Sham-Controlled Study on The Efficacy And Safety of Near-Infrared Light Therapy Device in Participants With Mild-Moderate Alzheimer's Disease (NirsCure-03A)

NCT07262645•Danyang Huichuang Medical Equipment Co., Ltd.

View on ClinicalTrials.gov

Summary

This study is a multicenter, randomized, double-blind, placebo (sham device)-controlled clinical trial. A total of 320 patients with mild to moderate Alzheimer's disease (AD) are planned to be enrolled. Central stratified block randomization will be applied, with stratification based on disease severity (mild vs. moderate) and PET subgroup participation status (yes vs. no). Participants will be randomly assigned to either the treatment group or control group in a 1:1 ratio. After enrollment, participants will complete the treatment at home. The treatment group will receive therapy using a near-infrared light therapy device, while the control group will use sham device. Both investigators and participants will remain blinded to treatment allocation throughout the study.

Eligibility

Age

50 - 85 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•1. Male or female participants aged between 50 to 85 years old (inclusive).
•2. Participants must have at least 4 years of formal education and be capable of completing cognitive and other protocol-specified assessments.
•3. Documented progressive memory decline for ≥12 months prior to screening.
•4. Meets the core clinical diagnostic criteria for mild to moderate AD dementia (stages 4-5), according to the National Institute on Aging and the Alzheimer's Association (NIA-AA) 2018 research framework and the AA workgroup 2024 update.
•5. Evidence of positive brain amyloid pathology, demonstrated by at least one of the following:
•1. Positive Aβ-PET scan (historical positive result acceptable); or
•2. Positive Cerebrospinal fluid (CSF) Aβ testing (historical positive result acceptable).
•6. Mini-Mental State Examination (MMSE) total score between 15 and 26 inclusive (between 12 and 22 for participants with an elementary school education level).
•7. Clinical Dementia Rating (CDR) Global of 1 or 2, and the CDR-Memory Box scores ≥ 0.5.
•8. If receiving acetylcholinesterase inhibitor or memantine, participants must be on a stable dose for at least 12 weeks prior to baseline.
+2 more criteria

Exclusion Criteria

•1. Presence of any diagnosis other than AD that could cause dementia or cognitive decline, including but not limited to: vascular dementia; Central nervous system infections (e.g., HIV, neurosyphilis); Creutzfeldt-Jakob disease; Huntington's disease; Parkinson's disease; Lewy body dementia; Traumatic brain injury-related dementia; Dementia caused by physical and chemical factors (e.g., drug toxicity, alcohol intoxication, carbon monoxide poisoning); significant systemic diseases (e.g., hepatic or pulmonary encephalopathy); Intracranial space-occupying lesions (e.g., subdural hematoma, brain tumors); or dementia clearly attributable to endocrine disorders, vitamin deficiencies, or other identifiable causes.
•2. Brain MRI demonstrating significant pathological findings, including but not limited to:
•1. More than two infarcts with a diameter \> 2 cm, or a single infarct involving critical regions (thalamus, hippocampus, entorhinal cortex, parahippocampal cortex, angular gyrus, or other cortical and subcortical gray matter nuclei);
•2. Extensive white matter hyperintensities (Fazekas score ≥ 3);
•3. Space-occupying lesions such as cysts, abscesses, or brain tumors (e.g., meningiomas or arachnoid cysts). Specifically, meningiomas or arachnoid cysts with a maximum diameter \< 1 cm do not require exclusion.
•3. History of transient ischemic attack (TIA), stroke, or seizure within 6 months of screening.
•4. Hachinski Ischemic Score (HIS) \> 4.
•5. Hamilton Depression Rating Scale (HAMD-17) total score \> 10.
•6. Diagnosis of a psychiatric disorder according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) at screening, including schizophrenia or other psychotic disorders, bipolar disorder, major depressive disorder, or delirium.
•7. Known history or laboratory confirmation of HIV infection or neurosyphilis at screening.
+14 more criteria

Locations (23)

Peking University First Hospital

Beijing, Beijing Municipality, China

Beijing Friendship Hospital, Capital Medical University

Beijing, Beijing Municipality, China

Xuanwu Hospital, Capital Medical University

Beijing, Beijing Municipality, China

Peking University Third Hospital

Beijing, Beijing Municipality, China

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences

Beijing, Beijing Municipality, China

Shijiazhuang People's Hospital

Shijiazhuang, Hebei, China

Baotou Central Hospital

Baotou, Inner Mongolia, China

The Second Affiliated Hospital of Soochow University

Suzhou, Jiangsu, China

The First Affiliated Hospital of Soochow University

Suzhou, Jiangsu, China

Tangdu Hospital, Air Force Medical University

Xi'an, Shaanxi, China

Key Dates

Start Date

December 15, 2025

Primary Completion Date

July 22, 2027

Completion Date

July 22, 2027

Last Updated

December 3, 2025

Enrollment

320

ESTIMATED participants

Conditions

Alzheimer s Disease

Interventions

NirsCure 6000

DEVICE

Sham Device

DEVICE

Contacts

Yi Tang, MD, PhD

CONTACT

+86 13811021432 tangyi@xwhosp.org

Sponsors

Lead Sponsor

Danyang Huichuang Medical Equipment Co., Ltd.

Related Studies

ENROLLING_BY_INVITATIONNA

Multisensory Environment-Based Occupational Therapy for Alzheimer's Patients

NCT07279103

Alzheimer s DiseaseOccupational Therapy+5 more

ENROLLING_BY_INVITATIONNA

Personalized Brain Stimulation for Cognitive Impairment in Older Adults

NCT07208734

Alzheimer s Disease

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 3, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions